AbbVie (NYSE:ABBV) Shares Down 3.8% – Here’s What Happened

AbbVie Inc. (NYSE:ABBV) dropped 3.8% on Wednesday . The stock traded as low as $204.27 and last traded at $217.04. Approximately 15,265,070 shares were traded during trading, an increase of 101% from the average daily volume of 7,604,316 shares. The stock had previously closed at $225.66.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q4 beat and raised guidance — AbbVie reported adjusted Q4 EPS of $2.71 and revenue of $16.62B (both above consensus) and guided FY‑2026 adjusted EPS to $14.37–$14.57, underpinning near‑term earnings visibility. AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results
• Positive Sentiment: Immunology momentum — Skyrizi and Rinvoq drove double‑digit growth in the immunology portfolio and helped lift overall revenue ~10% YoY; management says newer immunology sales helped beat expectations. AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs
• Positive Sentiment: Pipeline expansion — AbbVie filed regulatory applications for Rinvoq (upadacitinib) in vitiligo, which would expand indications and provide additional growth optionality if approved. AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®)
• Neutral Sentiment: Analyst positioning mixed but not uniformly negative — some firms (Evercore/others) maintain bullish views citing immunology momentum and neurology upside, supporting longer‑term conviction. AbbVie Buy Thesis Anchored by Robust Immunology Momentum, Neurology Upside, and Long-Term IBD Defense
• Neutral Sentiment: Some commentators view the selloff as a buying opportunity given fundamentals and dividend/institional support, so technical buyers may step in at these levels. MarketBeat AbbVie coverage
• Negative Sentiment: Aesthetics and filler weakness — Allergan/Aesthetics (Botox/Juvederm) showed softer results and investor focus on “filler” weakness pressured the stock despite the companywide beat. AbbVie stock slides as investors focus on aesthetics weakness
• Negative Sentiment: Diversification concerns and a downgrade — some analysts question growth durability outside immunology as oncology and aesthetics declined, and one downgrade highlighted reliance on M&A and the exclusion of IPR&D/milestone costs from guidance. AbbVie’s Immunology Fortress Can’t Hide Cracks In Diversification (Downgrade)
• Negative Sentiment: Profit‑taking despite beat — commentary notes that Rinvoq and some oncology lines missed investor expectations and management excluded acquired IPR&D/milestone impacts from guidance, keeping uncertainty around 2026 cash/earnings assumptions. This helped trigger the selloff. AbbVie Beats on Q4 Earnings, Stock Down Despite Upbeat ’26 View

Analyst Upgrades and Downgrades

Several brokerages have issued reports on ABBV. Scotiabank began coverage on AbbVie in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 price objective for the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a report on Wednesday, January 21st. Raymond James Financial set a $256.00 price target on shares of AbbVie in a research report on Monday, November 3rd. Cantor Fitzgerald set a $250.00 price objective on shares of AbbVie and gave the company an “overweight” rating in a research report on Thursday, October 9th. Finally, HSBC upgraded shares of AbbVie from a “hold” rating to a “buy” rating and upped their target price for the stock from $225.00 to $265.00 in a research report on Wednesday, December 10th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and a consensus target price of $251.50.

AbbVie Stock Performance

The company has a market capitalization of $383.59 billion, a price-to-earnings ratio of 164.42, a P/E/G ratio of 0.93 and a beta of 0.35. The business’s 50-day simple moving average is $224.20 and its 200-day simple moving average is $219.16.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping the consensus estimate of $2.65 by $0.06. The company had revenue of $16.62 billion during the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. AbbVie’s revenue was up 10.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS. On average, analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Norges Bank acquired a new position in shares of AbbVie during the 2nd quarter worth about $4,288,200,000. Wellington Management Group LLP boosted its stake in AbbVie by 457.4% during the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock worth $2,439,714,000 after acquiring an additional 8,646,424 shares during the last quarter. Laurel Wealth Advisors LLC grew its holdings in AbbVie by 18,384.4% during the second quarter. Laurel Wealth Advisors LLC now owns 5,705,964 shares of the company’s stock valued at $1,059,141,000 after purchasing an additional 5,675,095 shares during the period. Vanguard Group Inc. increased its stake in AbbVie by 1.9% in the second quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock valued at $32,910,186,000 after purchasing an additional 3,380,842 shares in the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its holdings in AbbVie by 169.3% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 4,722,893 shares of the company’s stock worth $876,662,000 after purchasing an additional 2,969,202 shares during the period. 70.23% of the stock is currently owned by institutional investors.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.